FDA panel says Avandia should stay, but with restrictions

A sharply divided advisory committee recommends that the diabetes drug, which has been linked to increased heart attack risk, remain on the market with more supervision and stronger warnings. Faced with conflicting and less-than-conclusive scientific evidence, a Food and Drug Administration advisory panel recommended Wednesday that the controversial diabetes drug Avandia remain on the market — but with tighter supervision and increased warnings...

Read the whole article on LA Times - Science

More from LA Times - Science